Complementary roles of surgery and systemic treatment in clear cell renal cell carcinoma

医学 肾细胞癌 全身疗法 肿瘤科 疾病 免疫疗法 临床试验 内科学 肾癌 肾切除术 新辅助治疗 癌症 外科 重症监护医学 肾 乳腺癌
作者
Alexandre Ingels,Riccardo Campi,Umberto Capitanio,Daniele Amparore,Riccardo Bertolo,Umberto Carbonara,Selçuk Erdem,Önder Kara,Tobias Klatte,Maximilian C. Kriegmair,Michele Marchioni,M.C. Mir,Idir Ouzaïd,Nicola Pavan,Angela Pecoraro,Eduard Roussel,Alexandre de la Taille
出处
期刊:Nature Reviews Urology [Nature Portfolio]
卷期号:19 (7): 391-418 被引量:73
标识
DOI:10.1038/s41585-022-00592-3
摘要

Standard-of-care management of renal cell carcinoma (RCC) indisputably relies on surgery for low-risk localized tumours and systemic treatment for poor-prognosis metastatic disease, but a grey area remains, encompassing high-risk localized tumours and patients with metastatic disease with a good-to-intermediate prognosis. Over the past few years, results of major practice-changing trials for the management of metastatic RCC have completely transformed the therapeutic options for this disease. Treatments targeting vascular endothelial growth factor (VEGF) have been the mainstay of therapy for metastatic RCC in the past decade, but the advent of immune checkpoint inhibitors has revolutionized the therapeutic landscape in the metastatic setting. Results from several pivotal trials have shown a substantial benefit from the combination of VEGF-directed therapy and immune checkpoint inhibition, raising new hopes for the treatment of high-risk localized RCC. The potential of these therapeutics to facilitate the surgical extirpation of the tumour in the neoadjuvant setting or to improve disease-free survival in the adjuvant setting has been investigated. The role of surgery for metastatic RCC has been redefined, with results of large trials bringing into question the paradigm of upfront cytoreductive nephrectomy, inherited from the era of cytokine therapy, when initial extirpation of the primary tumour did show clinical benefits. The potential benefits and risks of deferred surgery for residual primary tumours or metastases after partial response to checkpoint inhibitor treatment are also gaining interest, considering the long-lasting effects of these new drugs, which encourages the complete removal of residual masses.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Lucas的应助被科研通管家采纳,获得10
刚刚
深情安青的应助被科研通管家采纳,获得10
刚刚
刚刚
隐形曼青的应助被科研通管家采纳,获得10
刚刚
顾矜的应助被科研通管家采纳,获得10
刚刚
天天快乐的应助被科研通管家采纳,获得10
刚刚
orixero的应助被科研通管家采纳,获得30
刚刚
充电宝的应助被科研通管家采纳,获得10
1秒前
阿努比斯的应助被科研通管家采纳,获得30
1秒前
英姑的应助被科研通管家采纳,获得10
1秒前
syvshc的应助被科研通管家采纳,获得10
1秒前
syvshc的应助被科研通管家采纳,获得10
1秒前
言默发布了新的文献求助10
1秒前
打打的应助被科研通管家采纳,获得10
1秒前
ohhhhhoho完成签到,获得积分10
1秒前
ding的应助被科研通管家采纳,获得10
1秒前
2秒前
英姑的应助被科研通管家采纳,获得10
2秒前
2秒前
DOC_XIONG的应助被科研通管家采纳,获得10
2秒前
2秒前
2秒前
莱因哈特别着急完成签到,获得积分10
2秒前
molihuakai的应助被Lz采纳,获得10
2秒前
3秒前
杨德帅发布了新的文献求助10
3秒前
3秒前
三千完成签到,获得积分10
3秒前
科研通AI6.4的应助被平生采纳,获得10
4秒前
所所的应助被LL采纳,获得10
4秒前
4秒前
4秒前
肖肖发布了新的文献求助20
4秒前
bakerwm发布了新的文献求助10
5秒前
5秒前
Ming发布了新的文献求助10
5秒前
烟花的应助被山东科技李采纳,获得10
5秒前
5秒前
zyl完成签到 ,获得积分10
6秒前
1518完成签到,获得积分10
6秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8186382
求助须知:如何正确求助?哪些是违规求助? 9574807
关于积分的说明 21838252
捐赠科研通 7784045
什么是DOI,文献DOI怎么找? 3434752
关于科研通互助平台的介绍 2559164
邀请新用户注册赠送积分活动 2481535